Expression and Significance of CD44, CD47 and c-met in Ovarian Clear Cell Carcinoma
Open accessAbstract
Aims: The aim of the present study is to investigate the differential expression of CD44, CD47 and c-met in ovarian clear cell carcinoma (OCCC), the correlation in their expression and their relationship with the biological behavior of OCCC. Methods: We used immunohistochemistry to examine the expression of CD44, CD47 and c-met in OCCC (86 cases) and investigated the effects of the expression and interaction of these molecules on the development of OCCC. Results: CD44, CD47 and c-met expression was significantly high in OCCC. Expression of CD44 and CD47 correlated with patient surgical stage, chemotherapy resistance and prognosis (all p < 0.05), and expression of c-met correlated with chemotherapy resistance and prognosis (all p < 0.05), but did not correlate with lymph node metastasis (all p > 0.05). The surgical stage, CD44, CD47 and c-met expression were independent risk factors for OCCC prognosis (all p < 0.05). Patients with low levels of CD44, CD47 and c-met showed better survival than those with high levels (all p < 0.05). There was a positive correlation between CD44 (or CD47) and c-met, as well as between CD44 and CD47 (the Spearman correlation coefficient rs was 0.783, 0.776 and 0.835, respectively, all p < 0.01). Additionally, pairwise correlation analysis of these three markers shows that the high expression of CD44/CD47, CD44/c-met and CD47/c-met were correlated with patient surgical stage, chemotherapy resistance and prognosis (all p < 0.05), but did not correlate with lymph node metastasis (all p > 0.05). Conclusions: Expression of CD44, CD47 and c-met was upregulated in OCCC and pairwise correlation. CD44, CD47 and c-met may have synergistic effects on the development of OCCC and are prognostic factors for ovarian cancer.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Increased CD47 levels on malignant cells correlate with dismal prognosis in AML, esophageal carcinoma, and ovarian cancer.
“increased CD47 levels on the surface of malignant cells correlate with dismal prognosis in subjects with AML, esophageal carcinoma, and ovarian cancer [888–891].”
From Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. (2018) · cites this paper as [888]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 30 · Cited by 83
Research works printed but not linked: 2
- Baohui, J.; Yuting, H.; Jing, T.; Hui F.; Linping H.; Weiping Y.; Quan H. In vitro application of anti-CD47 monoclonal antibody for targeted therapy of ovarian cancer. Chin. J. Clin. Oncol. 2013, 40, 440-443.
- Damm, S.; Koefinger, P.; Stefan, M.; Wels, C.; Mehes, G.; Richtig, E.; Kerl, H.; Otte, M.; Schaider, H. HGF Promotes Motility in Primary Human Melanocytes through CD44v6 via a NF-κB/Egr-1/C/EBP-β complex. J. Investig. Dermatol. 2010, 130, 1893-1903.
- Authors
- Wang, H., Tan, M., Zhang, S., Li, X., Gao, J., Zhang, D., Hao, Y., Gao, S., Liu, J., & Lin, B.
- Affiliations
- Sheng Jing Hospital (CN)
- Corresponding author
- Lin, Bei
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2015-02-04
- Volume
- 16
- Issue
- 2
- Pages
- 3391-3404
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC4346902
- OpenAlex
- W1964091411
- Cited by
- 83
- References
- 30
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 13 · 2023: 8 · 2022: 8 · 2021: 7 · 2020: 7 · 2019: 4 · 2018: 7 · 2017: 8 · 2016: 13 · 2015: 5
- FWCI
- 12.54
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (20112104120019, 2013-03, 81101527, 20112104110016, 81172491, 81472437)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Keywords
- ovarian clear cell carcinoma, CD44, CD47, c-Met, prognostic factors, chemoresistance, surgical stage, lymph node metastasis, survival, protein expression correlation
- MeSH terms
- Adult, Aged, Female, Humans, Immunohistochemistry, Lymphatic Metastasis, Middle Aged, Neoplasm Staging, Ovarian Neoplasms, Prognosis, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Adenocarcinoma, Clear Cell, Hyaluronan Receptors, Proto-Oncogene Proteins c-met, CD47 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
